Solving Atypical Protein Expression With Transposases

By Kayla Bean, AGC Biologics

Cell line development (CLD) is essential for biopharmaceutical success, but creating complex proteins like bispecifics and trispecifics introduces significant hurdles in expression and stability. Traditional random integration methods often lead to genetic instability and unpredictable ratios in these intricate molecules. However, utilizing innovative technologies like semi-targeted integration via transposase platforms can overcome these issues.

Transposases ensure full gene sequences are inserted into active chromatin, significantly boosting titers and maintaining stability. Partnering with an experienced CDMO provides access to these flexible platforms and high-throughput screening, which can analyze thousands of clones simultaneously. This expertise mitigates risks of cost overruns and timeline delays, transforming CLD uncertainty into a reliable path toward scalability and commercialization. By leveraging advanced vector design and automated screening, researchers can efficiently identify top candidates and ensure high-quality, stable production for even the most challenging atypical molecules.